OQROGet OQRO Pro
Insider trade

Gilead Sciences (GILD)Officer sold ~$390K

Johanna Mercier, Officer at Gilead Sciences, sold ~$390K of Gilead Sciences shares.

~$390K
Approx. value · 3,000 sh @ $129.92
121K
Holds after · shares reported
Traded
Jul 15, 2026
Filed
Jul 16, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 27, 2026CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
  2. May 6, 2026Congress · 1 personMembers of Congress: 2 purchases
  3. May 14, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)
  4. May 15, 2026Insider · 2 peopleInsiders: 5 sales (~$4.1M)
  5. May 22, 2026FDAFDA drug approval: Hepcludex
  6. May 22, 2026Government · Federal Register noticeNotice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
  7. Jun 1, 2026Insider · 1 personInsiders: 3 sales (~$2.0M)
  8. Jun 15, 2026Insider · 2 peopleInsiders: 4 sales (~$748K)
  9. Jun 24, 2026FDAFDA drug approval: Trodelvy
  10. Jun 24, 2026FDAFDA drug approval: Trodelvy
  11. Jul 1, 2026Insider · 1 personInsiders: 2 sales (~$1.9M)
  12. Jul 15, 2026 · this disclosureInsiderOfficer sold ~$390K of GILD shares in the open market

What came next

  1. Jul 15, 2026InsiderCFO sold ~$390K of GILD shares in the open market
  2. Aug 3, 2026Insider · 1 personInsiders: 3 sales (~$2.0M)
  3. Aug 4, 2026Company filing · Form 8-K · ResultsReported its results
  4. Aug 17, 2026Insider · 2 peopleInsiders: 3 sales (~$4.3M)
  5. Aug 20, 2026Insider · 1 personInsiders: 5 sales (~$725K)
  6. Aug 26, 2026Insider · 1 personInsiders: 4 sales (~$2.7M)
  7. Aug 27, 2026FDAFDA drug approval: Bixlenvo Sunlenca Starter Pack (Copackaged)
  8. Aug 27, 2026FDAFDA drug approval: Sunlenca
  9. Aug 27, 2026FDAFDA drug approval: Bixlenvo
  10. Aug 27, 2026FDAFDA drug approval: Sunlenca
  11. Sep 1, 2026Insider · 1 personInsiders: 3 sales (~$2.2M)
  12. Sep 15, 2026Insider · 2 peopleInsiders: 4 sales (~$869K)
  13. Oct 1, 2026Insider · 1 personInsiders: 2 sales (~$2.2M)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Gilead Sciences

For Gilead Sciences, OQRO holds 28 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 78 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its GILD page.

Other recent filings by Johanna Mercier, Chief Comm & Corp Aff Officer

The full history of Johanna Mercier, Chief Comm & Corp Aff Officer is on the profile page.

How this filing works

Other disclosures at Gilead Sciences

Everything OQRO holds on this company is on its GILD page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data